Back to search results

RANT-GC Trial: Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers

This study, called the RANT-GC Trial, is looking at how well a new approach to chemotherapy works for people with stomach or gastroesophageal junction (where the esophagus meets the stomach) cancer. You might be eligible if you have Stage IB, II, or III adenocarcinoma that can be treated with chemotherapy before surgery. The study will use different chemotherapy combinations like FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, or PACLITAXEL with or without CARBOPLATIN. The main goal is to see what percentage of participants complete their planned treatment. This study plans to enroll 20 people, but its current status is unclear.

Study design
This is a Phase 1b, single-arm, open-label study. It is designed to determine the effectiveness and feasibility of a response-guided approach to chemotherapy.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 3 years to measure the percentage who complete their treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05733689

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Recruiting
PHASE1Ages 18+InterventionalTreatment
University of California, Irvine
~20 participants
Updated 2026-03-10 on ClinicalTrials.gov
What's tested:FLOTFOLFOXFOLFIRIFOLFIRINOXPACLITAXEL with or without CARBOPLATINDOCETAXEL and IRINOTECAN (alone or combined)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of completing per protocol treatment.
Measured over Up to 3 years

Conditions

Gastroesophageal Adenocarcinoma

Explore related trials

Esophageal Adenocarcinoma

NCT05733689

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Chao Family Comprehensive Cancer Center, University

    Orange, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Farshid Dayyani, MD,PhD · PRINCIPAL_INVESTIGATOR · Chao Family Comprehensive Cancer Center

Who to contact

Chao Family Comprehensive Cancer Center University of California, Irvine
[email protected]
1-877-827-8839
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must have histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEA). Other GE histologies which are treated per NCCN guidelines for neoadjuvant treatment are eligible.
Must have Stage IB, II or Stage III GEA eligible for (neo)adjuvant doublet or triplet chemotherapy for up to 6 months.
Age ≥ 18 years Because the safety or efficacy of neoadjuvant chemotherapy for LGEA has not been tested or established for patients \<18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.
Performance status: ECOG performance status ≤2
Life expectancy of greater than 6 months
Adequate organ and marrow function as defined below:
Docetaxel can cause fetal harm and irinotecan is known to be teratogenic. Since these compounds are part of the treatment regimens, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
Ability to understand and the willingness to sign a written informed consent. 1. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial.

Exclusion

Patients may not be receiving any other investigational agents.
Patients with known distant metastases from GEA.
History of allergic reactions attributed to agents used in study.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
History of another primary cancer which requires active treatment or is expected to require treatment within 12 months after enrollment.
Inability to comply with study and follow-up procedures as judged by the Investigator.
Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.
Patients with prior organ/bone marrow/non-autologous stem cell transplants

What this trial measures

  • Percentage of completing per protocol treatment.Up to 3 years

    Percent of patients who will undergo attempt at curative intent resection.